Treating myelomas

Abstract

This document provides methods and materials related to treating myelomas. For example, methods and materials re-lating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.

1 . A method for treating a mammal having myeloma, said method comprising administering to said mammal a composition comprising nanoparticles containing albumin and paclitaxel complexed with an anti-CD38 polypeptide antibody, wherein an average diameter of the nanoparticles is less than 1 μm. 
     
     
         2 - 3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein the anti-CD38 polypeptide antibody is Daratumumab, MOR202, SAR650984, or any combination thereof. 
     
     
         5 . The method of  claim 1 , wherein said composition comprises an alkylating agent complexed with said nanoparticles. 
     
     
         6 . The method of  claim 5 , wherein said alkylating agent is a platinum compound. 
     
     
         7 . The method of  claim 6 , wherein said platinum compound is carboplatin. 
     
     
         8 . The method of  claim 1 , wherein said anti-CD38 polypeptide antibody is a humanized antibody. 
     
     
         9 . The method of  claim 1 , wherein said anti-CD38 polypeptide antibody is a chimeric antibody. 
     
     
         10 . The method of  claim 1 , wherein said composition is administered by injection. 
     
     
         11 . The method of  claim 1 , wherein administering the composition increases a length of progression-free survival in the mammal. 
     
     
         12 - 15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein administering the composition increases a time to progression. 
     
     
         17 - 25 . (canceled) 
     
     
         26 . The method of  claim 1 , wherein said composition comprises an anti-inflammatory agent. 
     
     
         27 - 33 . (canceled) 
     
     
         34 . The method of  claim 1 , wherein said administration of said composition increases a median time to progression for a population of mammals with said myeloma to at least 150 days. 
     
     
         35 . The method of  claim 1 , wherein said administration of said composition increases a median time to progression for a population of mammals with said myeloma is at least 165 days. 
     
     
         36 . The method of claim  17 , wherein said administration of said composition increases a median time to progression for a population of mammals with said myeloma is at least 170 days. 
     
     
         37 . The method of  claim 1 , wherein the average diameter of the nanoparticles is from 0.1 μm to 0.3 μm. 
     
     
         38 . The method of  claim 1 , wherein the average diameter of the nanoparticles is from 0.15 μm to 0.3 μm. 
     
     
         39 . The method of  claim 1 , wherein the average diameter of the nanoparticles is from 0.2 μm to 0.5 μm. 
     
     
         40 . The method of  claim 1 , wherein the average diameter of the nanoparticles is from 0.3 μm to 0.5 μm. 
     
     
         41 . The method of  claim 1 , wherein the average diameter of the nanoparticles is from 0.2 μm to 0.8 μm. 
     
     
         42 . The method of  claim 1 , wherein the average diameter of the nanoparticles is from 0.2 μm to 0.7 μm. 
     
     
         43 - 72 . (canceled)